E Kettner

Summary

Affiliation: Otto-von-Guericke University
Country: Germany

Publications

  1. pmc Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
    Alexander Stein
    Tumor Biology Center Freiburg, Breisacher Str, 117, 79106 Freiburg, Germany
    BMC Cancer 13:454. 2013
  2. ncbi request reprint [Adequate supportive treatment in therapeutic use of "biologicals" for GI tumours in oncosurgery--what does the surgeon need to know?]
    E Kettner
    Klinik für Radiologie and Nuklearmedizin, Universitätsklinikum Magdeburg A ö R, Magdeburg, Germany
    Zentralbl Chir 138:204-9. 2013

Collaborators

  • Alexander Stein
  • Dirk Arnold
  • Joachim Zimber
  • Dirk Behringer
  • Albrecht Kretzschmar
  • Karl Heinz Pflüger
  • Susanna Hegewisch-Becker
  • Thomas Wolff
  • Andreas Kirsch

Detail Information

Publications2

  1. pmc Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
    Alexander Stein
    Tumor Biology Center Freiburg, Breisacher Str, 117, 79106 Freiburg, Germany
    BMC Cancer 13:454. 2013
    ..Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking...
  2. ncbi request reprint [Adequate supportive treatment in therapeutic use of "biologicals" for GI tumours in oncosurgery--what does the surgeon need to know?]
    E Kettner
    Klinik für Radiologie and Nuklearmedizin, Universitätsklinikum Magdeburg A ö R, Magdeburg, Germany
    Zentralbl Chir 138:204-9. 2013
    ....